Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
J Allergy Clin Immunol Pract ; 6(3): 803-811, 2018.
Article in English | MEDLINE | ID: mdl-29133220

ABSTRACT

BACKGROUND: Behavioral interventions focusing on exercise and healthy diet improve asthma control in obese patients with asthma, but whether these interventions can lead to improvements in nonobese patients remains unclear. OBJECTIVES: In a randomized, controlled parallel-group design, we studied the effects of an 8-week intervention of either exercise (high-intensity interval training), diet (high protein/low glycemic index), or a combination of the 2, on asthma control and clinical outcomes in nonobese patients with asthma. METHODS: Nonobese adult patients with asthma (n = 149) were randomized to 1 of 4 groups: an exercise group, a diet group, an exercise + diet group, or a control group. Outcomes included Asthma Control Questionnaire (ACQ) score, asthma-related quality-of-life (Asthma-Related Quality-of-Life Questionnaire [AQLQ]) score, inflammatory cell counts in induced sputum, FEV1, fractional exhaled nitric oxide, and airway hyperresponsiveness (AHR). RESULTS: A total of 125 patients completed the study and were included in the data analysis. Patients in the exercise + diet group improved the ACQ score from 1.9 ± 0.7 to 1.0 ± 0.7 and the AQLQ score from 5.2 ± 0.8 to 6.2 ± 0.7, which was statistically significant when compared with changes in the control group (P < .05 and <.01, respectively). The exercise group and the diet group did not improve either the ACQ score or the AQLQ score significantly compared with the control group and there were no significant changes in sputum cell counts, FEV1, fractional exhaled nitric oxide, or AHR within any groups following the intervention period. CONCLUSIONS: The combination of exercise and diet improves asthma control in nonobese patients, but does not affect AHR or airway inflammation.


Subject(s)
Asthma/therapy , Diet , Exercise Therapy , Adult , Asthma/immunology , Asthma/metabolism , Asthma/physiopathology , Eosinophils/immunology , Humans , Leukocyte Count , Middle Aged , Nitric Oxide/metabolism
2.
Thorax ; 65(12): 1107-10, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20965928

ABSTRACT

AIMS: Unexplained chronic cough is a common condition with no satisfactory treatments. Previous work has suggested that cough may be linked to neutrophilic airway inflammation. This study tested the hypothesis that long-term low-dose erythromycin reduces the induced sputum neutrophil count and 24 h cough frequency in patients with unexplained chronic cough. METHODS: 30 patients with an unexplained chronic cough lasting more than 8 weeks were randomly assigned to take 250 mg erythromycin once daily (n=15) or placebo (n=15) for 12 weeks in a double-blind parallel group study. Cough frequency, cough reflex sensitivity and cough severity were assessed at baseline, 6, 12 and 24 weeks. The primary outcome measure was change in 24 h cough frequency at 12 weeks. RESULTS: There was no difference in the change in cough frequency between the erythromycin and placebo groups at 12 weeks (mean difference in fold change 1.1; 95% CI 0.7 to 1.5; p=0.585) or at other times. There was a statistically significant between-treatment difference in the change in sputum neutrophils at 12 weeks (−10.2% vs +6.6% with erythromycin and placebo; mean difference 16.8%; 95% CI 1.6 to 32.1; p=0.03) but not at other times. There was no difference in the change in other measures of cough between treatments. CONCLUSIONS: Treatment with low-dose erythromycin for 12 weeks reduces the induced sputum neutrophil count but not cough frequency or severity in patients with unexplained chronic cough.


Subject(s)
Antitussive Agents/administration & dosage , Cough/drug therapy , Erythromycin/administration & dosage , Aged , Antitussive Agents/therapeutic use , Capsaicin , Chronic Disease , Double-Blind Method , Drug Administration Schedule , Erythromycin/therapeutic use , Female , Humans , Leukocyte Count , Male , Middle Aged , Neutrophils/drug effects , Neutrophils/pathology , Sensory System Agents , Treatment Outcome
4.
J Allergy Clin Immunol ; 123(5): 1083-9, 1089.e1-7, 2009 May.
Article in English | MEDLINE | ID: mdl-19368965

ABSTRACT

BACKGROUND: Budesonide/formoterol maintenance and reliever therapy maintains asthma control and reduces exacerbation frequency compared with higher fixed-dose combination regimens. Its effects on eosinophilic airway inflammation and structure are unknown. OBJECTIVE: We sought to compare the effects of budesonide/formoterol 200/6 microg twice daily plus as-needed with budesonide/formoterol 800/12 microg twice daily on airway eosinophils and remodeling. METHODS: This 52-week, parallel-group, randomized, double-blind study of 127 asthma patients who were symptomatic despite therapy compared (1) the change between induced sputum percent eosinophils at baseline and the geometric mean of 4 on-treatment values and (2) the change in endobronchial biopsy eosinophil counts pre- and post-treatment. RESULTS: Mean daily doses of budesonide/formoterol were 604/18 microg in the maintenance and reliever therapy group and 1,600/24 microg in the high fixed-dose group. In the former, the geometric mean percent sputum eosinophils remained unchanged (1.6% to 1.9%), whereas biopsy specimen subepithelial eosinophils increased (6.2 to 12.3 cells/mm(2)). Sputum and biopsy eosinophil counts decreased with high fixed-dose treatment (2.2% to 1.2% and 7.7 to 4.8 cells/mm(2), respectively), resulting in significant treatment differences of 0.7% (ratio, 1.8; 95% CI, 1.2-2.8; P = .0038) and 7.5 cells/mm(2) (ratio, 2.9; 95% CI, 1.6-5.3; P < .001), respectively. There were no between-treatment differences in reticular basement membrane thickness, exhaled nitric oxide, exacerbation frequency, or FEV(1). CONCLUSION: Compared with fixed-dose combination treatment containing a 4-fold higher maintenance dose of budesonide, budesonide/formoterol maintenance and reliever therapy is associated with higher eosinophil counts, but these remain within the range associated with stable clinical control.


Subject(s)
Asthma/drug therapy , Bronchodilator Agents/therapeutic use , Budesonide/therapeutic use , Eosinophils/immunology , Ethanolamines/therapeutic use , Inflammation/drug therapy , Administration, Inhalation , Adolescent , Adult , Aged , Asthma/immunology , Blood Cell Count , Bronchodilator Agents/administration & dosage , Budesonide/administration & dosage , Double-Blind Method , Eosinophils/metabolism , Ethanolamines/administration & dosage , Female , Formoterol Fumarate , Humans , Inflammation/immunology , Male , Middle Aged , Young Adult
5.
Respir Res ; 8: 67, 2007 Sep 27.
Article in English | MEDLINE | ID: mdl-17897478

ABSTRACT

BACKGROUND: Few studies have compared treatment strategies in patients with asthma poorly controlled on low dose inhaled corticosteroids, and little is known about the effects of different treatments on airway inflammation. In this double-blind, placebo-controlled, parallel group study, we compared the effects of salmeterol plus fluticasone propionate (FP) (Seretide; SFC) and FP plus montelukast (FP/M) on sputum inflammatory markers, airway responsiveness, lung function, and symptoms in adult asthmatics. METHODS: Sixty-six subjects were randomised to SFC or FP/M for 12 weeks. The primary outcome was changes in neutrophil, eosinophil, macrophage, lymphocyte, and epithelial cell levels in induced sputum. Additional outcomes included the change in other sputum markers of airway inflammation, airway responsiveness, symptom control, and lung function. RESULTS: Both treatments had no significant effect on induced sputum inflammatory cells, although there was a trend for a reduction in sputum eosinophils. Both treatments significantly improved airway responsiveness, whereas SFC generally led to greater improvements in symptom control and lung function than FP/M. FP/M led to significantly greater reductions in sputum cysteinyl leukotrienes than SFC (treatment ratio 1.80; 95% CI 1.09, 2.94). CONCLUSION: Both treatments led to similar control of eosinophilic airway inflammation, although PEF and symptom control were better with SFC. STUDY NUMBER: SAM40030 (SOLTA).


Subject(s)
Acetates/therapeutic use , Adrenergic beta-Agonists/therapeutic use , Albuterol/analogs & derivatives , Androstadienes/therapeutic use , Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Bronchial Hyperreactivity/drug therapy , Leukotriene Antagonists/therapeutic use , Quinolines/therapeutic use , Acetates/adverse effects , Adrenergic beta-Agonists/adverse effects , Adult , Albuterol/adverse effects , Albuterol/therapeutic use , Androstadienes/adverse effects , Anti-Asthmatic Agents/adverse effects , Asthma/metabolism , Asthma/pathology , Asthma/physiopathology , Bronchial Hyperreactivity/metabolism , Bronchial Hyperreactivity/pathology , Bronchial Hyperreactivity/physiopathology , Cyclopropanes , Cysteine/metabolism , Double-Blind Method , Drug Combinations , Female , Fluticasone , Fluticasone-Salmeterol Drug Combination , Forced Expiratory Volume/drug effects , Histamine/metabolism , Humans , Interleukin-8/metabolism , Leukotriene Antagonists/adverse effects , Leukotrienes/metabolism , Lung/drug effects , Lung/physiopathology , Male , Quinolines/adverse effects , Spirometry , Sputum/cytology , Sputum/drug effects , Sputum/metabolism , Sulfides , Time Factors , Treatment Outcome , United Kingdom
6.
Respir Med ; 101(8): 1652-8, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17481879

ABSTRACT

Many patients with asthma remain symptomatic with impaired airway function on inhaled steroids. This study investigates the relationship between the clinical effect seen in response to additional treatment and the effect on airway inflammatory indices. Seventy-five adult asthmatic patients, incompletely controlled on 800 mcg budesonide/day, were randomised following a 4 week run-in period, to a double-blind, multi-centre controlled clinical trial of doubling inhaled corticosteroid (budesonide 1600 mcg/day) or adding 10mg montelukast for 12 weeks. Induced sputum was collected at baseline and end of treatment and analysed for eosinophil and neutrophil percentages, leukotrienes C4, D4 and E4, IL-8, Eosinophil Cationic Protein (ECP) and histamine. Sputum evidence of inflammation (2.0% eosinophils) was seen in only 29% of these patients and the percentage of eosinophils and other markers of airway inflammation did not change over the study period in either treatment group. There were significant improvements in am PEF (montelukast: 31.7 L/min, budesonide: 32.3 L/min) and quality of life with both treatments. We conclude that while both treatments showed similar improvements in lung function and quality of life, there was no evidence from these sputum markers measured that the effects were mediated via a reduction in airway inflammation or that the level of pre-treatment markers was associated with outcome.


Subject(s)
Acetates/administration & dosage , Anti-Asthmatic Agents/administration & dosage , Asthma/drug therapy , Bronchodilator Agents/administration & dosage , Budesonide/administration & dosage , Quinolines/administration & dosage , Administration, Inhalation , Adolescent , Adult , Aged , Cyclopropanes , Double-Blind Method , Female , Humans , Male , Middle Aged , Sputum/drug effects , Sulfides , Treatment Outcome
7.
N Engl J Med ; 354(7): 697-708, 2006 Feb 16.
Article in English | MEDLINE | ID: mdl-16481637

ABSTRACT

BACKGROUND: The development of tumor necrosis factor alpha (TNF-alpha) antagonists has made it feasible to investigate the role of this cytokine in refractory asthma. METHODS: We measured markers of TNF-alpha activity on peripheral-blood monocytes in 10 patients with refractory asthma, 10 patients with mild-to-moderate asthma, and 10 control subjects. We also investigated the effects of treatment with the soluble TNF-alpha receptor etanercept (25 mg twice weekly) in the patients with refractory asthma in a placebo-controlled, double-blind, crossover pilot study. RESULTS: As compared with patients with mild-to-moderate asthma and controls, patients with refractory asthma had increased expression of membrane-bound TNF-alpha, TNF-alpha receptor 1, and TNF-alpha-converting enzyme by peripheral-blood monocytes. In the clinical trial, as compared with placebo, 10 weeks of treatment with etanercept was associated with a significant increase in the concentration of methacholine required to provoke a 20 percent decrease in the forced expiratory volume in one second (FEV1) (mean difference in doubling concentration changes between etanercept and placebo, 3.5; 95 percent confidence interval, 0.07 to 7.0; P=0.05), an improvement in the asthma-related quality-of-life score (by 0.85 point; 95 percent confidence interval, 0.16 to 1.54 on a 7-point scale; P=0.02), and a 0.32-liter increase in post-bronchodilator FEV1 (95 percent confidence interval, 0.08 to 0.55; P=0.01). CONCLUSIONS: Patients with refractory asthma have evidence of up-regulation of the TNF-alpha axis. (ClinicalTrials.gov number, NCT00276029.).


Subject(s)
Asthma/drug therapy , Asthma/metabolism , Immunoglobulin G/therapeutic use , Receptors, Tumor Necrosis Factor/therapeutic use , Tumor Necrosis Factor-alpha/metabolism , ADAM Proteins/biosynthesis , ADAM17 Protein , Adolescent , Adult , Aged , Asthma/physiopathology , Biomarkers/metabolism , Bronchial Hyperreactivity/drug therapy , Bronchial Hyperreactivity/metabolism , Case-Control Studies , Cross-Over Studies , Double-Blind Method , Etanercept , Female , Forced Expiratory Volume/drug effects , Humans , Immunologic Factors/therapeutic use , Male , Methacholine Chloride , Middle Aged , Monocytes/metabolism , Pilot Projects , Receptors, Tumor Necrosis Factor, Type I/biosynthesis , Treatment Outcome , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/biosynthesis , Up-Regulation
8.
Am J Respir Crit Care Med ; 173(7): 736-43, 2006 Apr 01.
Article in English | MEDLINE | ID: mdl-16424444

ABSTRACT

RATIONALE: No currently available treatment is reported to reduce the exaggerated airway wall inflammation of chronic obstructive pulmonary disease. OBJECTIVES: We tested the hypothesis that inhaled combined long-acting beta2-agonist (salmeterol) and corticosteroid (fluticasone propionate) will reduce inflammation. METHODS: Bronchial biopsies and induced sputum were taken from 140 current and former smokers (mean age, 64 yr) with moderate to severe disease, randomized in a 13-wk double-blind study to placebo (n = 73) or salmeterol/fluticasone propionate 50/500 microg (n = 67) twice daily. Biopsies were repeated at 12 wk and sputa at 8 and 13 wk. After adjustment for multiplicity, comparisons between active and placebo were made for median change from baseline in the numbers of biopsy CD8+ and CD68+ cells/mm2 and sputum neutrophils. MEASUREMENTS AND MAIN RESULTS: Combination therapy was associated with a reduction in biopsy CD8+ cells of -118 cells/mm2 (95% confidence interval [CI], -209 to -42; p = 0.02), a reduction of 36% over placebo (p = 0.001). CD68+ cells were unaffected by combination treatment. Sputum differential (but not total) neutrophils reduced progressively and, at Week 13, significantly with combination treatment (median treatment difference, 8.5%; 95% CI, 1.75%-15.25%; p = 0.04). The combination also significantly reduced biopsy CD45+ and CD4+ cells and cells expressing genes for tumor necrosis factor-alpha and IFN-gamma and sputum total eosinophils (all p < or = 0.03). These antiinflammatory effects were accompanied by a 173-ml (95% CI, 104-242; p < 0.001) improvement in prebronchodilator FEV1. CONCLUSIONS: The combination of salmeterol and fluticasone propionate has a broad spectrum of antiinflammatory effects in both current and former smokers with chronic obstructive pulmonary disease, which may contribute to clinical efficacy.


Subject(s)
Adrenergic beta-Agonists/therapeutic use , Albuterol/analogs & derivatives , Androstadienes/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Pulmonary Disease, Chronic Obstructive/drug therapy , Administration, Inhalation , Adrenergic beta-Agonists/administration & dosage , Adult , Aged , Aged, 80 and over , Albuterol/administration & dosage , Albuterol/therapeutic use , Androstadienes/administration & dosage , Anti-Inflammatory Agents/administration & dosage , Biopsy , Bronchoscopy , CD4-Positive T-Lymphocytes/pathology , CD8-Positive T-Lymphocytes/pathology , Double-Blind Method , Drug Therapy, Combination , Female , Fluticasone , Follow-Up Studies , Forced Expiratory Volume/drug effects , Humans , Leukocyte Count , Male , Middle Aged , Neutrophils/pathology , Pulmonary Disease, Chronic Obstructive/pathology , Pulmonary Disease, Chronic Obstructive/physiopathology , Salmeterol Xinafoate , Sputum/cytology , Treatment Outcome
9.
Chest ; 126(6): 1811-4, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15596678

ABSTRACT

STUDY OBJECTIVES: Sputum induction is increasingly used as a research technique and as a clinical tool. In order to evaluate abnormal results, normal ranges need to be fully developed. Although a number of studies have described normal ranges, none have investigated the effect of the age of the subject on these results. This study was undertaken to assess whether there are age-related differences in sputum cell differential cell counts in a population of normal, healthy volunteers. STUDY DESIGN AND PARTICIPANTS: Induced sputum samples were obtained from 66 healthy, nonsmoking subjects (24 men) with a mean age of 44 years (age range, 18 to 74 years). Differential cell counts were related to age. RESULTS: Sputum neutrophil counts were found to correlate significantly with the age of the volunteers (r = 0.58; p < 0.001). Macrophage counts showed a proportionate, inverse correlation with increasing age (p < 0.01), but no correlation was seen for any other cell type. On subanalysis according to age range, the mean neutrophil differential increased from 26.9% (SD, 19.8%) [17 patients] in the group of patients who were 0 to 29 years of age to 68.5% (SD, 20.6%) [11 patients] in the group of patients who were > 60 years of age. CONCLUSION: In our healthy volunteer population, the induced sputum differential neutrophil count increased significantly with age. These findings highlight the need for age matching in controlled studies.


Subject(s)
Sputum/cytology , Adolescent , Adult , Aged , Aging/pathology , Cell Count , Epithelial Cells/cytology , Female , Humans , Leukocyte Count , Macrophages/cytology , Male , Middle Aged , Reference Values
10.
Am J Respir Crit Care Med ; 169(1): 15-9, 2004 Jan 01.
Article in English | MEDLINE | ID: mdl-14512269

ABSTRACT

Previous studies have shown evidence of airway inflammation in patients with chronic cough and have suggested that the cough may be due to release of tussive mediators and activation of afferent sensory nerve endings. We measured the concentration of various proinflammatory and tussive mediators in induced sputum supernatants from 20 patients with cough variant asthma or eosinophilic bronchitis, 20 patients with nonasthmatic chronic cough, 22 patients with idiopathic chronic cough, and 18 healthy control subjects. We measured histamine, cysteinyl-leukotrienes, prostanoids (prostaglandin D2 and prostaglandin E2), and interleukin-8 by enzyme immunoassay. The median sputum histamine concentrations were significantly higher in patients with idiopathic chronic cough (8.0 ng/ml) and cough variant asthma/eosinophilic bronchitis (10.2 ng/ml) than in normal subjects (2.6 ng/ml; 95% confidence interval of difference from idiopathic chronic cough, 0.8 to 25.8 [p = 0.009] and 95% confidence interval of difference from cough variant asthma/eosinophilic bronchitis, 1.1 to 20.1 [p = 0.01]). Median sputum prostaglandin D2 and prostaglandin E2 concentrations were significantly higher in all categories of chronic cough. Our findings support the view that there is release of inflammatory and tussive mediators in patients with chronic cough and suggest that there might be similarities in the mechanism of cough in a diverse range of conditions.


Subject(s)
Bronchoalveolar Lavage Fluid/chemistry , Cough/metabolism , Inflammation Mediators/analysis , Adult , Analysis of Variance , Asthma/complications , Bronchial Provocation Tests , Bronchitis, Chronic/complications , Case-Control Studies , Chronic Disease , Cohort Studies , Cough/etiology , Female , Humans , Male , Middle Aged , Probability , Prognosis , Reference Values , Sensitivity and Specificity , Severity of Illness Index , Sputum/chemistry , Statistics, Nonparametric
11.
Am J Respir Crit Care Med ; 168(8): 976-82, 2003 Oct 15.
Article in English | MEDLINE | ID: mdl-12816740

ABSTRACT

Cilomilast (Ariflo), a new oral phosphodiesterase-4 selective inhibitor, improves lung function in chronic obstructive pulmonary disease (COPD). We have evaluated its antiinflammatory effects in 59 patients with COPD randomized to receive cilomilast, 15 mg two times a day, or placebo for 12 weeks. Induced sputum differential cell counts were obtained at baseline and at five further visits. Interleukin-8 and neutrophil elastase were measured in sputum supernatant. Bronchial biopsies obtained at baseline and at Week 10 were immunostained and counted for neutrophils, CD8+ and CD4+ T-lymphocyte subsets, and CD68+ macrophages. Cells expressing the genes for interleukin-8 and tumor necrosis factor-alpha were identified by in situ hybridization and quantified. Compared with placebo, analysis of variance (ANOVA) of the change from baseline showed that cilomilast did not alter any sputum endpoint or FEV1. However, bronchial biopsies demonstrated that cilomilast treatment was associated with reductions in CD8+ (p = 0.001; ANOVA) and CD68+ cells (p < 0.05; ANOVA). In addition, by Poisson analysis, comparison of cell counts analyzed as a ratio of active to placebo demonstrated reductions of CD8+ (48% p < 0.01) and CD68+ (47% p = 0.001) cells. This is the first demonstration of reduction by any agent of airway tissue inflammatory cells characteristic of COPD. Phosphodiesterase-4 inhibitors represent a promising new class of substances for use in antiinflammatory treatment of this disease.


Subject(s)
3',5'-Cyclic-AMP Phosphodiesterases/antagonists & inhibitors , Anti-Inflammatory Agents/therapeutic use , Bronchodilator Agents/therapeutic use , Phosphodiesterase Inhibitors/therapeutic use , Pulmonary Disease, Chronic Obstructive/drug therapy , Adult , Aged , Aged, 80 and over , Anti-Inflammatory Agents/immunology , Antigens, CD/analysis , Antigens, CD/drug effects , Antigens, Differentiation, Myelomonocytic/analysis , Antigens, Differentiation, Myelomonocytic/drug effects , Biopsy , Bronchodilator Agents/immunology , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/immunology , Carboxylic Acids , Cyclic Nucleotide Phosphodiesterases, Type 4 , Cyclohexanecarboxylic Acids , Double-Blind Method , Female , Forced Expiratory Volume/drug effects , Humans , Interleukin-8/analysis , Interleukin-8/immunology , Leukocyte Count , Leukocyte Elastase/analysis , Leukocyte Elastase/drug effects , Male , Middle Aged , Nitriles , Phosphodiesterase Inhibitors/immunology , Pulmonary Disease, Chronic Obstructive/immunology , Pulmonary Disease, Chronic Obstructive/physiopathology , Sputum/chemistry , Sputum/cytology , Treatment Outcome
12.
Lancet ; 360(9347): 1715-21, 2002 Nov 30.
Article in English | MEDLINE | ID: mdl-12480423

ABSTRACT

BACKGROUND: Treatment decisions in asthma are based on assessments of symptoms and simple measures of lung function, which do not relate closely to underlying eosinophilic airway inflammation. We aimed to assess whether a management strategy that minimises eosinophilic inflammation reduces asthma exacerbations compared with a standard management strategy. METHODS: We recruited 74 patients with moderate to severe asthma from hospital clinics and randomly allocated them to management either by standard British Thoracic Society asthma guidelines (BTS management group) or by normalisation of the induced sputum eosinophil count and reduction of symptoms (sputum management group). We assessed patients nine times over 12 months. The results were used to manage those in the sputum management group, but were not disclosed in the BTS group. The primary outcomes were the number of severe exacerbations and control of eosinophilic inflammation, measured by induced sputum eosinophil count. Analyses were by intention to treat. FINDINGS: The sputum eosinophil count was 63% (95% CI 24-100) lower over 12 months in the sputum management group than in the BTS management group (p=0.002). Patients in the sputum management group had significantly fewer severe asthma exacerbations than did patients in the BTS management group (35 vs 109; p=0.01) and significantly fewer patients were admitted to hospital with asthma (one vs six, p=0.047). The average daily dose of inhaled or oral corticosteroids did not differ between the two groups. INTERPRETATION: A treatment strategy directed at normalisation of the induced sputum eosinophil count reduces asthma exacerbations and admissions without the need for additional anti-inflammatory treatment.


Subject(s)
Anti-Asthmatic Agents/therapeutic use , Asthma/drug therapy , Beclomethasone/therapeutic use , Bronchodilator Agents/therapeutic use , Eosinophils , Leukocyte Count , Sputum/metabolism , Adult , Aged , Asthma/metabolism , Female , Humans , Male , Middle Aged , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...